Fairvalue-Calculator Fairvalue-Calculator
EN DE

Lineage Cell Therapeutics, Inc (LCTX) Fair Value & Analysis

Healthcare · US · Market cap $302M

Price$1.25
Fair Value$0.8000
Upside-36.0%
Quality94/100
Evidence: Low Range $0.6000 – $1.01

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Lineage Cell Therapeutics, Inc (LCTX) currently trades at $1.25, while our model-based Fair Value estimate is $0.8000 — implying the stock looks roughly 36.0% overvalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the …

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is Lineage Cell Therapeutics, Inc (LCTX) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $0.8000 versus a price of $1.25 — about −36% (overvalued). Model-based estimate, not financial advice.
What is the fair value of LCTX?
Our 21-model fair value for Lineage Cell Therapeutics, Inc is $0.8000 (as of Jun 24, 2026), built from audited fundamentals. The current price is $1.25.
What is the quality score of LCTX?
Lineage Cell Therapeutics, Inc has a Quality Score of 94/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.